|Home | About | Journals | Submit | Contact Us | Français|
Stargardt disease 3 (STGD3) is a juvenile macular dystrophy caused by mutations in the elongase of very long-chain fatty acids-like 4 (ELOVL4) gene, which encodes an elongase involved in the production of extremely long-chain fatty acids. The STGD3-related mutations cause production of C-terminally truncated proteins (ELOVL4ΔC). STGD3 is transmitted in an autosomal dominant manner. To date, molecular mechanisms of this pathology have been proposed based solely on the interaction between wild-type ELOVL4 and ELOVL4ΔC. However, analyses of Elovl4ΔC knockin mice revealed reduced levels of not only ELOVL4 substrates, but also of fatty acids with a broad spectrum of chain lengths. Therefore, we investigated the molecular mechanisms responsible for ELOVL4ΔC affecting the entire very long-chain fatty acid (VLCFA) elongation pathway.
The ELOVL4ΔC protein was expressed in HEK 293T cells, and its effect on elongase activities toward several acyl-CoAs were examined. We also investigated the homo- and hetero-oligomerization of ELOVL4ΔC with other elongases (ELOVL1–7) or with other enzymes involved in VLCFA elongation using coimmunoprecipitation experiments.
We found that ELOVL4ΔC forms a homo-oligomer more strongly than wild-type ELOVL4. ELOVL4ΔC also interacts strongly with other elongases, although similar interactions for wild-type ELOVL4 were observed as only weak. In addition, ELOVL4ΔC is able to form an elongase complex by interacting with other components of the VLCFA elongation machinery, similar to wild-type ELOVL4.
We propose that not only the ELOVL4-ELOVL4ΔC homo-oligomeric interaction, but also several hetero-oligomeric interactions, may contribute to the pathology of STGD3.
Stargardt disease 3 (STGD3) is a juvenile-onset macular dystrophy, characterized by gradual loss of central vision, accumulation of lipofuscin, and window defects in the macula [1,2]. STGD3, which is transmitted in an autosomal dominant manner, is caused by mutations in the elongase of very long-chain fatty acids-like 4 (ELOVL4) gene, which encodes an elongase involved in the production of extremely long-chain fatty acids (FAs) . The highest expression of ELOVL4 mRNA has been observed in the retina, followed by the skin, brain, and testis [3,4]. To date, three types of ELOVL4 mutations have been found in STGD3 patients . All of these mutations result in a C-terminally truncated version (ELOVL4ΔC) of the protein. In addition, as the wild-type protein normally carries an endoplasmic reticulum (ER) retention signal in its C-terminus, all three mutations also cause a loss of the ER retention signal. Subsequently, while wild-type ELOVL4 is localized in the ER, ELOVL4ΔC is mislocalized to the Golgi or aggresomes [5-7]. Furthermore, coexpression of ELOVL4ΔC with wild-type ELOVL4 results in the mislocalization of the wild-type protein due to its interaction with the mutated protein [6-8]. This effect is considered to be the molecular basis for the autosomal dominant transmission of STGD3.
Very long-chain fatty acids (VLCFAs), FAs with a chain length of ≥C20, function in numerous cellular processes, including sphingolipid biogenesis, inflammation, immunity, fetal growth and development, retinal function, and brain development [9-11]. VLCFA elongation occurs in the ER on acyl-CoAs by adding two carbon units in each cycle, and is composed of four steps: condensation, reduction, dehydration, and reduction . The second and fourth reduction steps are catalyzed by the reductases 3-ketoacyl-CoA reductase (KAR) and trans-2,3-enoyl-CoA reductase (TER), respectively , while 3-hydroxyacyl-CoA dehydratase (HACD) proteins (HACD1–4) are responsible for the third step, catalyzing the dehydration of 3-hydroxyacyl-CoA . The first step of the VLCFA elongation, condensing malonyl-CoA and acyl-CoA, is rate-limiting, and is catalyzed by one of seven elongases (ELOVL1–7) [10,14]. ELOVL1–7 differ in substrate specificities [10,15]. The substrates of ELOVL4 are predicted to be fatty acyl-CoAs with extremely long chain-lengths (≥C26) [16-18]. Such FAs exist only in certain tissues. Saturated FAs are observed in skin and are used in the formation of ceramides, the major lipid components of stratum corneum. Elovl4 knockout mice die soon after birth due to defects in skin barrier formation . On the other hand, polyunsaturated, extremely long FAs are found in the retina, sperm, and brain .
In addition to the Elovl4 knockout mice, Elovl4ΔC knockin mice have been generated and used as a model for STGD3 [17,18]. The phenotype of homozygous knockin mice resembles that of the Elovl4 knockout mice: They die within a few hours after birth, exhibiting severe defects in skin barrier formation [17,18]. This would suggest that the Elovl4ΔC protein has no enzyme activity. In addition, heterozygous Elovl4ΔC knockin mice display STGD3-like phenotypes such as progressive photoreceptor degeneration and the accumulation of lipofuscin in the retinal pigment epithelium . Quantitative lipid analyses have demonstrated that the levels of retinal phosphatidylcholines with C32-C36 polyunsaturated FAs (PUFAs) are reduced in the heterozygous Elovl4ΔC knockin mice . Unexpectedly, though, not only these ELOVL4 products, but also FAs with a broad spectrum of acyl-chain lengths, are affected in retinas by the Elovl4ΔC mutation . This implies that the entire VLCFA elongation machinery is affected by the Elovl4ΔC protein. In the present study, we determined that the expression of ELOVL4ΔC does indeed result in the inhibition of elongase activities toward C16:0-, C18:0-, C18:3(n-6)-, and C20:4(n-6)-CoAs in vitro. We also found that ELOVL4ΔC interacts with other ELOVLs, in addition to its already established homo-oligomeric interaction with wild-type ELOVL4. Inhibition of the entire VLCFA elongation pathway due to hetero-oligomer formation may contribute, at least partly, to the pathology of STGD3.
HEK 293T cells were grown on 0.3% collagen-coated dishes in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, St. Louis, MO) containing 10% fetal bovine serum and supplemented with 100 units/ml penicillin and 100 μg/ml streptomycin.
Transfections were performed using Lipofectamine PlusTM Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Cells were grown to ~60% confluency in six-well dishes, and medium was changed to 0.8 ml OPTI-MEM I Reduced-Serum Medium (Invitrogen) 10 min before transfection. Plasmid DNAs (0.5 μg) were diluted into 100 μl OPTI-MEM I, and 4 μl PLUS reagent was added to the DNA solution. After a 15 min incubation at room temperature, DNA-PLUS solution was mixed with 3 μl Lipofectamine reagent diluted with 100 μl OPTI-MEM I, and the mixture was incubated at room temperature for 15 min. The DNA-PLUS-Lipofectamine reagent complex was then added to cells. After incubation at 37 °C for 3 h, the medium was removed and replaced with normal medium.
The pCE-puro HA-1 and the pCE-puro His6-Myc-1 plasmids are mammalian expression vectors designed to produce an N-terminal HA-tagged protein and an N-terminal tandemly oriented His6 and a Myc epitope (His6-Myc)-tagged protein, respectively. The pCE-puro HA-ELOVLx (where x is each ELOVL number) plasmids have been described previously . The pCE-puro His6-Myc-ELOVL4 plasmid was constructed by cloning the ELOVL4 gene from the pCE-puro HA-ELOVL4 plasmid into the pCE-puro His6-Myc-1 vector.
The KAR and TER genes were amplified from an expressed sequence tag (EST) clone (ID 3622879; Open Biosystems, Huntsville, AL) and from human liver cDNA (Clontech [TAKARA Bio], Palo Alto, CA), respectively, by PCR using primers (for KAR, 5′-AGG ATC CAT GGA GAG CGC TCT CCC CGC CGC CG-3′ [BamHI site underlined] and 5′-TTT AGT TCT TCT TGG TTT TCT TCA GAT AG-3′; and for TER, 5′-AGG ATC CAT GAA GCA TTA CGA GGT GGA GAT TCT G-3′ [BamHI site underlined] and 5′-TTC AGA GCA GGA AGG GGA TGA TGG GC-3′). The resulting fragments were first cloned into pGEM-T Easy vector (Promega, Madison, WI), generating the pGEM-KAR and pGEM-TER plasmids. The pCE-puro HA-KAR and pCE-puro HA-TER plasmids were constructed by cloning the BamHI-NotI fragments of each of the pGEM-KAR and pGEM-TER plasmids into a pCE-puro HA-1 vector.
The pCE-puro His6-Myc-ELOVL4ΔC and pCE-puro HA-ELOVL4ΔC plasmids were constructed as follows. The ELOVL4 gene with a deletion at its 3′-terminus was amplified by PCR using the primers 5′-AGG ATC CAT GGG GCT CCT GGA CTC GGA GCC GG-3′ (BamHI site underlined) and 5′-CAA TCA GCT TCA TAT TTC TCT TTC TTT AAA-3′ from the pCE-puro HA-ELOVL4 plasmid. The amplified fragment was first cloned into the pGEM-T Easy vector, and the BamHI-NotI fragment of the resulting plasmid was transferred to the pCE-puro HA-1 vector or pCE-puro His6-Myc-1 vector, producing the pCE-puro HA-ELOVL4ΔC and pCE-puro His6-Myc-ELOVL4ΔC plasmids, respectively.
In vitro FA elongation assays were performed essentially as described elsewhere  using total membrane fractions. Cells were suspended in buffer A (50 mM HEPES-NaOH [pH 6.8], 150 mM NaCl, 10% glycerol, 1× protease inhibitor mixture [CompleteTM EDTA free; Roche Diagnostics, Indianapolis, IN], 1 mM PMSF, and 1 mM DTT) and lysed by sonication. After ultracentrifugation (100,000× g, 30 min, 4 °C), the pellet was suspended in buffer A and was used as the total membrane fraction. Total membrane fractions (20 μg protein in 19.5 μl buffer A) were each mixed with 25 μl of 2× assay buffer (300 mM potassium phosphate buffer [pH 6.8], 10% glycerol, 4 mM MgCl2, 2 mM CaCl2, 2 mM NADPH, 1× protease inhibitor mixture, 1 mM PMSF, and 1 mM DTT), 2.5 μl of 1 mM acyl-CoA (Avanti Polar Lipids, Alabaster, AL) complexed with 4 mg/ml FA-free BSA (Sigma), and 3 μl of 25 μCi/ml [14C]malonyl-CoA (55 mCi/mmol; Moravek Biochemicals, Brea, CA). After a 30 min incubation period at 37 °C, the reactions were terminated by adding 25 μl 75% KOH (w/v) and 50 μl ethanol, then saponified at 70 °C for 1 h, and acidified by adding 100 μl of 5 N HCl with 50 μl of ethanol. Lipids were extracted with 750 μl hexane and dried, then suspended in 30 μl chloroform and separated by normal phase thin layer chromatography (TLC) on LK5DF Silica Gel 150A TLC plates (Whatman, Kent, UK) with hexane/diethyl ether/acetic acid (30:70:1, v/v) as the solvent system. Labeled FAs were detected and quantified by a bioimaging analyzer BAS-2500 (Fuji Photo Film, Tokyo, Japan).
When FAs (eicosapentaenoic acid [EPA] or docosapentaenoic acid [DPA]) were used in place of acyl-CoAs, total membrane fractions (20 μg protein in 17.83 μl buffer A) were each mixed with 25 μl of 2× assay buffer, 0.5 μl of 5 mM FAs (Sigma), 1.67 μl of 0.3 M ATP, 2 μl of 5 mM CoA, and 3 μl of 25 μCi/ml [14C]malonyl-CoA. After termination of the reactions, lipids were saponified, acidified, extracted, and separated by TLC, followed by detection and quantification by a bioimaging analyzer BAS-2500, as described above.
Statistical analyses were performed by a two-tailed Student t test using Microsoft Excel software (Microsoft Corporation, Redmond, WA).
Immunoblotting was performed as described previously  using the anti-HA antibody HA-7 (1:2,000 dilution; Sigma), the anti-Myc antibody PL14 (0.5 μg/ml; Medical & Biologic Laboratories, Nagoya, Japan), or the anti-calnexin (H-10) antibody (0.2 μg/ml; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as the primary antibody and horse radish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG F(ab’)2 fragment (each from GE Healthcare Bio-Sciences, Piscataway, NJ, and diluted 1:7500) as the secondary antibody. Labeling was detected using ECLTM Reagents or an ECL plus System for Western Blotting Detection (both from GE Healthcare Bio-Sciences).
HEK 293T cells were transfected with two plasmids, one carrying HA-tagged genes and the other harboring Myc-tagged genes. Twenty-four hours after transfection, the cells were washed twice with PBS, suspended in buffer B (50 mM HEPES-NaOH (pH 7.4), 150 mM NaCl, 10% glycerol, 1× protease inhibitor mixture, 1 mM PMSF, and 1 mM DTT), and sonicated. After a centrifugation at 300× g for 3 min at 4 °C, the resulting supernatant was treated with 1% Triton X-100 for 30 min at 4 °C, to solubilize membranes. Samples were centrifuged at 100,000× g for 30 min at 4 °C, and the supernatant was incubated overnight at 4 °C with the anti-HA antibody HA-7 conjugated to agarose (Sigma). The gel was washed twice with buffer B containing 0.1% Triton X-100, suspended in 2× sodium dodecyl sulfate (SDS) sample buffer, and incubated for 5 min at 37 °C. The obtained precipitates were separated by SDS–PAGE (PAGE), and subjected to immunoblotting with the HA7 antibody or an anti-Myc PL14 antibody.
We recently performed comprehensive in vitro analyses examining substrate specificities of all ELOVLs using [14C]malonyl-CoA and 11 acyl-CoAs (C16:0-, C18:0-, C18:1(n-9)-, C18:2(n-6)-, C18:3(n-3)-, C18:3(n-6)-, C20:0-, C20:4(n-6)-, C22:0-, C24:0-, or C26:0-CoA). In those studies ELOVL4 exhibited activity toward C24:0- and C26:0-CoAs, but had no activity toward the other acyl-CoAs . The phenotype of homozygous Elovl4ΔC knockin mice resembles that of the Elovl4 knockout mice [17,18], suggesting that the Elovl4ΔC protein has no enzyme activity. However, to date, the enzyme activity of ELOVL4ΔC has not been directly examined. Therefore, we constructed an ELOVL4ΔC plasmid encoding an HA-tagged mutant ELOVL4 protein, which has a truncation of the C-terminal 51 amino acid residues, and expressed the protein in HEK 293T cells (Figure 1A). We then performed an in vitro FA elongase assay using total membrane proteins prepared from HEK 293T cells overproducing HA-ELOVL4 or HA-ELOVL4ΔC, together with [14C]malonyl-CoA and C24:0-CoA or C26:0-CoA. Consistent with our previous results , wild-type ELOVL4 exhibited enzyme activity toward both C24:0-CoA and C26:0-CoA (Figure 1B). In contrast, ELOVL4ΔC had no activity toward either substrate.
Reportedly, in cell lines that do not express significant levels of ELOVL4 mRNA, the expression of Elovl4 and subsequent treatment with the FAs EPA (C20:5(n-3)) or DPA (C22:5(n-3)) resulted in the production of C28 to C38 PUFAs . However, reported results were unclear as to whether these FAs were direct substrates of ELOVL4, since no biochemical analysis was performed. Therefore, we performed an in vitro FA elongase assay using HEK 293T cells overproducing HA-ELOVL4. Since C22:5(n-3)-CoA is not commercially available, we used ATP, CoA, and EPA or DPA, in place of C20:5(n-3)-CoA or C22:5(n-3)-CoA. In this assay system, EPA or DPA is converted to C20:5(n-3)-CoA or C22:5(n-3)-CoA, respectively, by endogenous acyl-CoA synthase using ATP and CoA. For use as controls, HEK 293T cells were also transfected with vector or with a plasmid encoding HA-ELOVL2 or HA-ELOVL5. Immunoblotting demonstrated that ELOVL4 was expressed at levels comparable to those of ELOVL2 and ELOVL5 (Figure 1A). Consistent with previous reports [21,24,25], ELOVL2, and to a lesser extent, ELOVL5, exhibited activities toward EPA, and ELOVL2 was active toward DPA (Figure 1C). However, ELOVL4 had no activity toward either substrate (Figure 1C). These results suggest that neither C20:5(n-3)-CoA nor C22:5(n-3)-CoA is a substrate of ELOVL4.
Lipid composition analyses determined that in retinas of Elovl4ΔC knockin mice, not only levels of C32-C36 lipids, the putative direct products of ELOVL4, but also of lipids with a broad range of chain-length, are reduced [19,20]. This suggests that ELOVL4ΔC inhibits elongation reactions that are not catalyzed by ELOVL4. To exclude the possibility that long-term expression of Elovl4ΔC causes indirect metabolic or transcriptional changes in lipid-related genes in the Elovl4ΔC knockin mice, we introduced ELOVL4ΔC into HEK 293T cells and analyzed its effects on endogenous elongase activities toward C16:0-, C18:0-, C18:3(n-6)-, and C20:4(n-6)-CoAs. In vitro analyses previously revealed the responsible ELOVLs active toward these acyl-CoAs: C16:0-CoA, ELOVL6; C18:0-CoA, ELOVL3 and ELOVL7; C18:3(n-6)-CoA, ELOVL5 and ELOVL7; C20:4(n-6)-CoA, ELOVL2 and ELOVL5 [10,15]. Forty-eight hours after transfection of the cells with vector or a plasmid encoding wild-type ELOVL4 or ELOVL4ΔC, total membrane proteins were prepared. Immunoblotting demonstrated that wild-type ELOVL4 and ELOVL4ΔC were expressed at similar levels (Figure 2A). Expression of wild-type ELOVL4 had no effect on the elongation of C16:0-, C18:0-, C18:3(n-6)-, or C20:4(n-6)-CoAs (Figure 2B), consistent with previous results indicating that these acyl-CoAs are not substrates for ELOVL4 . On the other hand, expression of ELOVL4ΔC resulted in a slight but statistically significant reduction in the products of all the tested elongation reactions (Figure 2B). These results suggest that ELOVL4ΔC inhibits the entire VLCFA elongation pathway.
The interaction between wild-type ELOVL4 and ELOVL4ΔC has already been established by coimmunoprecipitation, sucrose density gradient sedimentation, and native PAGE [6-8]. To compare the strength of interactions between ELOVL4-ELOVL4, ELOVL4-ELOVL4ΔC, and ELOVL4ΔC-ELOVL4ΔC, we performed coimmunoprecipitation experiments. HA-tagged ELOVL4 or ELOVL4ΔC was expressed in HEK 293T cells together with Myc-tagged ELOVL4 or ELOVL4ΔC, and each was subjected to coimmunoprecipitation with anti-HA antibodies, following membrane solubilization with the nonionic detergent Triton X-100. Myc-tagged ELOVL4 and Myc-tagged ELOVL4ΔC were each detected as two bands, which correspond to their glycosylated and unglycosylated forms  (Figure 3A). Expression of wild-type Myc-ELOVL4 alone did not result in its capture by anti-HA agarose beads (Figure 3A, lane 8). However, low levels of wild-type Myc-ELOVL4 were detected in immunoprecipitates with wild-type HA-ELOVL4 (Figure 3A, lane 9), suggesting a weak interaction. Although the Myc-tagged ELOVL4ΔC was expressed at levels lower than those of wild-type Myc-ELOVL4 (Figure 3A, lane 4), higher levels of the Myc-ELOVL4ΔC protein were observed in the immunoprecipitates of wild-type HA-ELOVL4 (Figure 3A, lane 10) than levels of wild-type Myc-ELOVL4 (Figure 3A, lane 9). These results suggest that the C-terminal deletion strengthens the ELOVL4 homointeraction. A similarly enhanced interaction was observed between HA-ELOVL4ΔC and wild-type Myc-ELOVL4 (Figure 3A, lane 11). Moreover, the interaction between HA-ELOVL4ΔC and Myc-ELOVL4ΔC was even stronger than the wild-type ELOVL4-ELOVL4ΔC interaction (Figure 3A, lane 12).
Since the expression of ELOVL4ΔC resulted in the inhibition of other elongation pathways not catalyzed by ELOVL4 (Figure 2B), we postulated that ELOVL4 inhibits other ELOVLs by hetero-oligomer interactions. To test this possibility, we performed coimmunoprecipitation analyses using anti-HA agarose beads, Myc-tagged ELOVL4, Myc-tagged ELOVL4ΔC, and HA-tagged ELOVLs. Although Myc-tagged wild-type ELOVL4 alone did not bind to anti-HA agarose (Figure 3B, lane 15), coexpression with one of the HA-tagged ELOVLs resulted in the recovery of Myc-tagged wild-type ELOVL4 in the immunoprecipitates, although its protein levels were low (Figure 3B, odd numbered lanes from 17 to 28). These results suggest that wild-type ELOVL4 interacts with all the ELOVLs, but only weakly. In contrast, the levels of Myc-ELOVL4ΔC in the immunoprecipitates of HA-ELOVLs were much higher than those of wild-type Myc-ELOVL4 (Figure 3B, even numbered lanes from 17 to 28), similar to interactions previously observed between ELOVL4 and ELOVL4ΔC (Figure 3A), suggesting strong interaction. These results indicate that ELOVL4ΔC forms not only homo-oligomers with wild-type ELOVL4 but also hetero-oligomers with other ELOVLs.
VLCFA elongation occurs by cycling through a four-step process, i.e., condensation, reduction, dehydration, and reduction. We recently revealed that enzymes responsible for each step interact with each other and form an elongase complex . To examine whether ELOVL4ΔC also engages in the elongase complex, we conducted coimmunoprecipitation analyses of the interactions between ELOVL4ΔC and the reductases KAR and TER, which catalyze the second and fourth steps of the VLCFA elongation cycle, respectively . HA-tagged KAR or TER was expressed in HEK 293T cells, together with Myc-tagged ELOVL4 or ELOVL4ΔC. Wild-type Myc-ELOVL4 or Myc-ELOVL4ΔC alone did not bind to anti-HA agarose beads (Figure 4, lanes 7 and 8). However, wild-type Myc-ELOVL4 was detected in immunoprecipitates with HA-KAR (Figure 4, lane 9) or with HA-TER (lane 11), indicating that wild-type ELOVL4 interacts with KAR and TER. ELOVL4ΔC also interacted with both KAR and TER, similar to results with the wild-type protein (Figure 4, lanes 10 and 12). Thus, ELOVL4ΔC can form the elongase complex.
STGD3 is an autosomal dominant macular dystrophy and is caused by mutations in the ELOVL4 gene [1,2]. ELOVL4 is an FA elongase whose substrates are considered to be fatty acyl-CoAs with ≥C26 carbon chain-length, identified using Elovl4 knockout mice and Elovl4ΔC knockin mice [16-18]. Others had reported that forced expression of Elovl4 in cells treated with the FA EPA (C20:5(n-3)) or DPA (C22:5(n-3)) produced PUFAs with chain-lengths of C28 to C38 . However, no direct biochemical analyses of ELOVL4 had been reported. We recently performed in vitro FA elongation assays using 11 different acyl-CoAs; these studies revealed that ELOVL4 is active only toward C24:0-CoA and C26:0-CoA . Here, we likewise found that neither EPA nor DPA is a substrate of ELOVL4 (Figure 1B). We speculate that C22:5(n-3)-CoA is first elongated by ELOVL2, then is further elongated by ELOVL4 to acyl-CoAs having ≥26 carbon chain-lengths.
To date, the autosomal dominant transmission of STGD3 has been thought to be caused only by the interaction between wild-type ELOVL4 and ELOVL4ΔC. However, in retinas from Elovl4ΔC knockin mice, the FA composition is broadly affected , implying that Elovl4ΔC inhibits the entire VLCFA elongation machinery. In the present study we demonstrated that expression of ELOVL4ΔC results in the inhibition of elongation reactions toward C16:0-, C18:0-, C18:3(n-6)-, and C20:4(n-6)-CoAs (Figure 2B). Although these effects are weak, their long-term influence may cause multiple types of damage in cellular functions, leading to the STGD3 pathology. Indeed, development of STGD3 appears in humans around 14 years of age and in Elovl4ΔC knockin mice at several months [19,27]. Although in Elovl4ΔC knockin mice and STGD3 patients, appearance of symptoms occurs relatively long after birth, in our culture system the effects of ELOVL4ΔC expression on the elongation of several FAs were observed within two days. The differences in the onset of the effect may be due to differences in the expression levels of ELOVL4ΔC. In Elovl4ΔC knockin mice or STGD3 patients, ELOVL4ΔC must be expressed at levels equivalent to the allelic wild-type ELOVL4. In our cultured cell systems, however, ELOVL4ΔC is expressed at much higher levels.
Since elongation reactions toward C16:0-, C18:0-, C18:3(n-6)-, and C20:4(n-6)-CoAs are catalyzed by other ELOVLs, we had postulated the existence of hetero-oligomeric interactions between ELOVL4ΔC and the other ELOVLs. Although wild-type ELOVL4 interacted with other ELOVLs only weakly, substantial levels of ELOVL4ΔC did indeed interact with other ELOVLs (Figure 3B). An enhancement of the homo-oligomeric interaction was also observed between the C-terminally truncated ELOVL4 and wild-type ELOVL4 (Figure 3A). To date, 3 mutations have been found in the ELOVL4 gene in STGD3 patients: a 5 bp deletion in exon 6 causing the loss of 51 amino acids at the C-terminus, a 2 bp deletion also leading to loss of the same 51 amino acids, and a nonsense mutation causing a 45 amino acid truncation . Thus, all mutations cause a loss of at least 45 amino acid residues at the C-terminus; we used the 51 amino acid truncation mutant for the ELOVL4ΔC in this study. ELOVL4 is a multispan membrane protein and may have seven transmembrane segments, by analogy to its yeast homolog Sur4 . The length of the C-terminal hydrophilic region (Arg268 to Asp314) is 47 amino acids. Therefore, the truncation of ELOVL4 observed in STGD3 causes complete or almost complete loss of the C-terminal hydrophilic region. Since this C-terminal region is the longest hydrophilic region in ELOVL4, it may contain residues important for function, protein–protein interaction, and maintenance of proper structure, in addition to the ER retention signal (Lys310-Ala311-Lys312-Gly313-Asp314) at the C-terminus. Although only deletion of the C-terminal ER retention signal has been emphasized in the pathology model of STGD3, we postulate that other residues in the C-terminal region may also be involved in this pathology. Loss of such residues may cause a conformational change in ELOVL4, leading to abnormal interactions with other ELOVLs.
In yeast, all components of VLCFA elongation form an elongase complex . Mammalian enzymes also form one or more elongase complex(es). We previously revealed that the 3-hydroxyacyl-CoA dehydratase HACD proteins interact with ELOVLs, with some preferences . HACD1 forms a complex not only with ELOVLs but also with the reductases KAR and TER . In the present study, we demonstrated that ELOVL4 interacts with KAR and TER (Figure 4). Mammalian FA synthase is a multienzyme that incorporates all catalytic activities of its cyclic reaction, which is similar to VLCFA elongation, as discrete domains on a single polypeptide chain . Like FA synthase, the adjacent positioning of the catalytic centers of the four elongation reactions of VLCFA elongation may contribute to efficient cycling.
ELOVL4ΔC interacts with other ELOVLs more strongly than the wild-type protein does, with apparently no specificity (Figure 3B). ELOVL4ΔC also interacts with KAR and TER, however in this case the strength of each interaction is comparable to that observed with the wild-type ELOVL4. Therefore, it is unlikely that ELOVL4ΔC binds to all proteins nonspecifically with a similar affinity. Nevertheless, we cannot exclude the possibility that ELOVL4ΔC also strongly interacts with other particular proteins and affects certain cellular functions. Since ELOVL4ΔC retains an ability to form the elongase complex, it is possible that ELOVL4ΔC competes with other ELOVLs when interacting with essential subunits of the elongase complex such as KAR and TER. In summary, we propose that several interactions, such as the already established ELOVL4-ELOVL4ΔC homo-oligomeric interaction, interactions with other ELOVLs, and interactions with other subunits of the elongase complex, contribute together to the pathology of STGD3.
We are grateful to Dr. E. A. Sweeney for scientific editing of the manuscript. This work was supported by a Grant-in-Aid for Young Scientists (A) (20687008) from the Ministry of Education, Culture, Sports, Sciences and Technology of Japan and by a grant from the ONO Medical Research Foundation.